Skip to main content

Table 2 Demographic and treatment plan-related data

From: Dose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without 18F-choline PET-CT detected simultaneous integrated boost

 

prostate with SIB (n = 46)

prostate only (n = 21)

patient age/years

median (range)

72 (59-83)

71 (61-81)

PTVprostate /cc

median (range)

142 (35-310)

163 (70-537)

PTVboost /cc

median (range)

17 (4-46)

-

% PSA ≤10 ng/mL

74%

76%

% Gleason score ≤6

65%

71%

% T-stage ≤2a

78%

86%

% NHT

17%

19%

bladder volume/cc

median (range)

237 (69-645)

225 (98-493)

rectum volume/cc

median (range)

88 (36-235)

81 (48-252)

EUD PTVprostate*/Gy

median (range)

76.7 (73.8-78.3)

76.0 (74.3-77.1)

EUD PTVboost /Gy

median (range)

79.5 (76.6-80.5)

-

EUD bladder/Gy

median (range)

55.6 (41.7-63.2)

54.6 (45.0-62.3)

EUD rectum/Gy

median (range)

55.9 (47.1-62.4)

54.6 (40.1-60.6)

NTCP bladder/%

median (range)

0 (0-0.6)

0 (0-0.4)

NTCP rectum/%

median (range)

6.9 (2.2-14.7)

5.5 (1.5-11.2)

  1. Abbreviations: PTV = planning treatment volume; PSA = prostate-specific antigen; NHT = neoadjuvant hormonal therapy; EUD = equivalent uniform dose; NTCP = normal tissue complication probability
  2. *p < 0.01